Matches in SemOpenAlex for { <https://semopenalex.org/work/W2948236883> ?p ?o ?g. }
Showing items 1 to 63 of
63
with 100 items per page.
- W2948236883 endingPage "P" @default.
- W2948236883 startingPage "1868" @default.
- W2948236883 abstract "The pathogenesis of NASH is a complex interaction among hepatic lipotoxicity, oxidative stress, mitochondrial dysfunction and ER stress leading to hepatic inflammation, cell death, and fibrosis. Bromocriptine, a dopamine D2 receptor agonist is known to reduce adipose lipolysis, plasma hyperFFAemia, and hepatic lipogenesis and inflammation. Also, the antidiabetes drug, bromocriptine-QR has been demonstrated to reduce cardiovascular events. Therefore, we investigated the impact of BC on hepatic pathophysiology in a mouse obesogenic dietary model of NASH. Six-week-old C57B6 male mice (N=8/gr) were maintained on a 40 kcal% fat diet with 5% fructose in the drinking water for 12 weeks to induce NASH then randomized to BC (10mg/kg) or vehicle daily treatment for an additional 3 weeks while maintained on the diet. A group of mice on normal diet was used as a normal reference control. Such BC therapy reduced plasma glucose (28.6%), insulin (31.4%), leptin (42.7%), cholesterol (21.9%) and body weight (14.2%) relative to vehicle (P<0.01). Also, plasma biomarkers of hepatic inflammation: elevated ALT, AST, and LPS, were reduced by BC (32.6, 38.8, and 38.1%, respectively, P<0.05) vs. vehicle. Treatment with BC significantly reduced four gene expression markers each for steatosis (SREBP1c, FASN, ACC1, PLIN2), fatty acid oxidation (PPARα, PGC1α, CPT1, UCP1), inflammation (TNFa, IL1β, MCP1, iNOS), ER stress (DDIT3, ATF, sXBP1, HSPA5), and fibrosis (αSMA, TGFβ, COL1A, TXNIP) by 16-76, 17-47, 31-75, 20-55, and 21-70%, respectively (P<0.05 for each gene). Finally, histological analysis of the liver revealed BC therapy reduced steatosis, inflammation, and ballooning degeneration resulting in a 63% reduced NAFLD activity score (2.6 vs. 7.1, P<0.01). The BC effects on NASH resulted in hepatic physiology closely resembling the normal diet control group. These results suggest that BC could be an effective therapy for NAFLD and NASH." @default.
- W2948236883 created "2019-06-14" @default.
- W2948236883 creator A5057497997 @default.
- W2948236883 creator A5084493896 @default.
- W2948236883 date "2019-06-01" @default.
- W2948236883 modified "2023-09-30" @default.
- W2948236883 title "1868-P: Bromocriptine (BC) Improves Hepatic Steatosis, Inflammation, and ER Stress in a Mouse Obesogenic Dietary Model of Nonalcoholic Steatohepatitis (NASH)" @default.
- W2948236883 doi "https://doi.org/10.2337/db19-1868-p" @default.
- W2948236883 hasPublicationYear "2019" @default.
- W2948236883 type Work @default.
- W2948236883 sameAs 2948236883 @default.
- W2948236883 citedByCount "1" @default.
- W2948236883 countsByYear W29482368832023 @default.
- W2948236883 crossrefType "journal-article" @default.
- W2948236883 hasAuthorship W2948236883A5057497997 @default.
- W2948236883 hasAuthorship W2948236883A5084493896 @default.
- W2948236883 hasConcept C126322002 @default.
- W2948236883 hasConcept C134018914 @default.
- W2948236883 hasConcept C2776175330 @default.
- W2948236883 hasConcept C2776856834 @default.
- W2948236883 hasConcept C2776914184 @default.
- W2948236883 hasConcept C2776954865 @default.
- W2948236883 hasConcept C2778772119 @default.
- W2948236883 hasConcept C2779064019 @default.
- W2948236883 hasConcept C2779134260 @default.
- W2948236883 hasConcept C2779478299 @default.
- W2948236883 hasConcept C3018708256 @default.
- W2948236883 hasConcept C71315377 @default.
- W2948236883 hasConcept C71924100 @default.
- W2948236883 hasConceptScore W2948236883C126322002 @default.
- W2948236883 hasConceptScore W2948236883C134018914 @default.
- W2948236883 hasConceptScore W2948236883C2776175330 @default.
- W2948236883 hasConceptScore W2948236883C2776856834 @default.
- W2948236883 hasConceptScore W2948236883C2776914184 @default.
- W2948236883 hasConceptScore W2948236883C2776954865 @default.
- W2948236883 hasConceptScore W2948236883C2778772119 @default.
- W2948236883 hasConceptScore W2948236883C2779064019 @default.
- W2948236883 hasConceptScore W2948236883C2779134260 @default.
- W2948236883 hasConceptScore W2948236883C2779478299 @default.
- W2948236883 hasConceptScore W2948236883C3018708256 @default.
- W2948236883 hasConceptScore W2948236883C71315377 @default.
- W2948236883 hasConceptScore W2948236883C71924100 @default.
- W2948236883 hasIssue "Supplement 1" @default.
- W2948236883 hasLocation W29482368831 @default.
- W2948236883 hasOpenAccess W2948236883 @default.
- W2948236883 hasPrimaryLocation W29482368831 @default.
- W2948236883 hasRelatedWork W1967972402 @default.
- W2948236883 hasRelatedWork W1973843004 @default.
- W2948236883 hasRelatedWork W1975023039 @default.
- W2948236883 hasRelatedWork W2018532964 @default.
- W2948236883 hasRelatedWork W2177968394 @default.
- W2948236883 hasRelatedWork W2320075075 @default.
- W2948236883 hasRelatedWork W2490983876 @default.
- W2948236883 hasRelatedWork W4200076256 @default.
- W2948236883 hasRelatedWork W4283021581 @default.
- W2948236883 hasRelatedWork W2133110686 @default.
- W2948236883 hasVolume "68" @default.
- W2948236883 isParatext "false" @default.
- W2948236883 isRetracted "false" @default.
- W2948236883 magId "2948236883" @default.
- W2948236883 workType "article" @default.